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To the Editor:
Neuropathy is one of the most common complica-
tions of both type 1 and type 2 diabetes. Patients
with diabetic neuropathy (DN) present with patho-
logical features, including impaired vascularity and
deficiency of angiogenic and neurotropic factors in
nerves. Among various etiologies described for DN,
hyperglycemia obviously plays an important role in
the onset and progression of disease. Therefore,
tight glycemic control and targeting glucose metabol-
ic pathways by specific agents seem to be useful
therapeutic strategies for halting the progression of
DN. However, clinically, these therapeutic ap-
proaches did not show desirable therapeutic efficacy
in the established neuronal damage. It underscores
the need for requirement of more efficient strategies
at the advanced stage of DN, including those
activating angiogenic and neurotrophic pathways.
Recently, cell therapy based on stem cells has been
suggested as an attractive strategy for the treatment
of DN [1].
Mesenchymal stromal cells (MSCs) are multipotent
cells, capable of moving toward sites of injury, releas-
ing various neurotrophic and angiogenic factors and
differentiating into multi-lineage cell types, particu-
larly neuron-like cells. These features make MSCs a
suitable candidate for cell-based therapeutic strate-
gies in DN [2]. Autologous MSCs, because they are
not subject to immune rejection in contrast to allo-
geneic MSCs, have been considered an excellent choice
for curative angiogenic and neurotrophic therapies
[3].
However, oxidative stress as a consequence of high
blood glucose causes serious damage to vital media-
tors in autologous MSCs. Our recent report
demonstrated that diabetic MSCs show reduced pro-
liferation rate and impaired paracrine effects including
secretion of angiogenic factors [4]. This highlighted
that the use of autologous diabetic MSCs as a source
for treating diabetic complications may still be con-
troversial. HIF-1 is illustrated as one of the impaired
vital mediators [4].
HIF-1, a transcription complex, consists of
HIF-1α that contains an oxygen-dependent degra-
dation domain, and HIF-1β. HIF-1α plays a central
role in the cellular responses to changes in oxygen
availability. Under low-oxygen conditions, HIF-1α
degradation via the ubiquitin-proteasome pathway is
inhibited. It leads to HIF-1α aggregation in the
nucleus and its binding to hypoxia-response ele-
ments in the promoters of target genes. HIF-1α
regulates the expression of potent angiogenic and
neurotrophic factors including vascular endothelial
growth factor, platelet-derived growth factor and
others [5]. However, protein stability and also
transactivation of HIF-1α protein are hampered
under oxidative stress. In a high-glucose context,
methylglyoxal level increased as a result of oxidative
stress and prevented binding of HIF-1α to its
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co-activator [6]. Another disturbing mechanism is
the sensitization of HIF-1α to degradation via the
ubiquitin- proteasome pathway that is driven by
high glucose [5]. It has been shown that pre-
conditioning of the cells by an antioxidant could
reverse impairment of HIF-1 function [6].
It is also well documented that efficacy of MSC
therapy is limited by the poor survival of stromal cells
after transplantation [7]. This situation is obviously
worsened by the diabetic condition because MSCs iso-
lated from a diabetic population show inherent lower
proliferating rate and viable cell fraction [4].The PI3K-
Akt pathway is an important mediator of cell
proliferation, growth, survival and angiogenesis in
various cell types, including MSCs.Thus, the agents
that over-activate this pathway in diabetic MSCs might
enhance efficacy of cell therapy [7].
Ferulic acid (FA) is a natural phytochemical com-
pound found in a large number of fruits and vegetables
with strong antioxidant activity.Through several mecha-
nisms, FA may correct the impaired functionality of
diabetic MSCs. A phenolic nucleus and unsaturated
side chain in the structure of FA are related to its an-
tioxidant activity [8]. Hence, FA may reverse high-
glucose-related damage in cells by preventing
methylglyoxal formation [9].
In a recent report, FA increased HIF-1α in mes-
senger RNA and protein levels and enhanced the
binding activity of HIF-1α through phosphoinositide-3
kinase (PI3K).Via the HIF-1 pathway, FA increases
the expression of various angiogenic andneuroprotective
factors, including vascular endothelial growth factor
and platelet-derived growth factor-BB [10].
Another mechanism is attenuation of MSC death
by FA pre-treatment. FA inhibits inactivation the PI3K/
Akt cascade in stressful conditions [11]. PI3K/Akt
pathway regulates multiple cellular processes includ-
ing cell survival and apoptosis. Akt translocation to
the nucleus results in phosphorylating certain tran-
scription factors, which contributes to cell survival [7].
Furthermore, the PI3K/Akt cascade induces the direct
induction of bcl-2, a key anti-apoptotic protein [7].
It was shown that FA treatment also inhibits stress-
related induction of the pro-apoptotic bax gene [12].
The ratio of bax/bcl-2 determines mitochondrial mem-
brane permeabilization, cytochrome C release and cell
apoptosis [7]. Furthermore, some evidence indicates
that MSCs differentiate into neuronal cells when
exposed to a high concentration of FA.These cells re-
semble neurons and glial cells, which simultaneously
express several neural proteins and are suitable for clin-
ical use [13]. However, there is a need to determine
the suitable concentrations and time for FA pre-
treatment, providing the best protective paracrine effect
along with initiating processes that differentiate cells
into neuron.
Taken together, pre-treating MSCs with FA may
serve as an effective tool to improve the efficacy of di-
abetic MSC transplantation for DN by improving the
paracrine effect and elevating the viability of diabet-
ic MSCs through affecting HIF-1a and PI3/Akt
pathway and, consequently, decreasing apoptosis and
accelerating MSCs differentiation into neurons
(Figure 1).
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